Alexion Pharmaceuticals Inc

NASDAQ: ALXN

  • Alexion Pharmaceuticals Inc
  • Sector

    Health Care
  • Industry

  • Company web

    Link
  • Employees

    Full Time Employees: 3,121
  • Executives

    • David Brennan
    • Ludwig Hantson
    • Paul Clancy
    • John Moriarty
    • Martin Mackay
    • Julie O'Neill
    • Edward Miller
    • Heidi Wagner
    • Brian Goff
    • Paul Friedman
  • Company address

    • 100 College Street
    • New Haven, CT 06510
    • United States of America
    • 1-203-272-2596
  • Investor Relation Site

    Link

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Alexion Pharmaceuticals Inc: Slide deck


Related companies

Teva Pharmaceutical Industries Limited

Health Care

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic...

Sanofi

Health Care

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher...

Smith & Nephew SNATS Inc

Health Care

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array...

Shire plc

Health Care

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas,...

Koninklijke Philips NV

Health Care

Koninklijke Philips N.V. operates as a health technology company worldwide. It offers diagnostic imaging solutions, magnetic resonance imaging, computed tomography, and diagnostic X-ray; advanced...

Novartis AG

Health Care

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for...